Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.

Joaquim Bellmunt Ronald de Wit Yves FradetMiguel A ClimentDaniel P PetrylakJae Lyun Lee Lawrence Fong Andrea Necchi Cora N Sternberg Peter H O'Donnell Thomas Powles Elizabeth R Plimack Dean F Bajorin Arjun V BalarDaniel CastellanoToni K Choueiri Stephane Culine Winald R Gerritsen Howard Gurney David I QuinnJacqueline VukyNicholas J Vogelzang Razvan CristescuJared LuncefordAssieh SaadatpourAndrey LobodaJunshui MaMohini RajasagiJames Luke GodwinBlanca Homet Moreno Petros D Grivas

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Multiple biomarkers characterizing the tumor microenvironment may help predict response to pembrolizumab monotherapy in UC, and potential clinical utility of these biomarkers may be context-dependent.

Keyphrases

advanced non small cell lung cancer
papillary thyroid
phase ii
high grade
clinical trial
open label
randomized controlled trial
squamous cell carcinoma
combination therapy
climate change
tyrosine kinase